JYNNEOS vaccination provides protection against mpox

Among men aged 18 to 49 years who are eligible for the JYNNEOS vaccine, mpox incidence is considerably higher among unvaccinated persons versus those who received one or two vaccine doses, according to research published in the Dec. 9 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Amanda B. Payne, Ph.D., from the CDC Mpox Emergency Response Team, and colleagues examined mpox incidence among unvaccinated but vaccine-eligible men and those who had received one or two doses of JYNNEOS vaccine using data for 9,544 reported mpox cases among men aged 18 to 49 years during July 31 to Oct. 1, 2022, from 43 U.S. jurisdictions.

The researchers found that mpox incidence among unvaccinated persons was 7.4 and 9.6 times that among persons who received one dose of JYNNEOS vaccine ≥14 days earlier or who received dose 2 ≥14 days earlier, respectively. Among vaccinated persons, the observed distribution of subcutaneous and intradermal routes of administration of dose 1 were not different from the expected distribution.

"These findings also suggest that JYNNEOS vaccination provides protection against mpox infection, irrespective of route of administration," the authors write. "Persons who are eligible for mpox vaccination should receive the complete recommended two-dose series to optimize their protection against mpox."

Copyright © 2022 HealthDay. All rights reserved.